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Therapy for non-Hodgkin’s lymphoma has progressed signiﬁcantly over the last decades.
However, the majority of patients remain incurable, and novel therapies are needed.
Because immunotherapy ideally offers target selectivity, an ever increasing number of
immunotherapies, both passive and active, are undergoing development. The champion
of passive immunotherapy to date is the anti-CD20 monoclonal antibody rituximab that
revolutionized the standard of care for lymphoma. The great success of rituximab cat-
alyzed the development of new passive immunotherapy strategies that are currently
undergoing clinical evaluation. These include improvement of rituximab efﬁcacy, newer
generation anti-CD20 antibodies, drug-conjugated and radio labeled anti-CD20 antibodies,
monoclonal antibodies targeting non-CD20 lymphoma antigens, and bispeciﬁc antibodies.
Active immunotherapy aims at inducing long-lasting antitumor immunity, thereby limiting
the likelihood of relapse. Current clinical studies of active immunotherapy for lymphoma
consist largely of vaccination and immune checkpoint blockade. A variety of protein- and
cell-based vaccines are being tested in ongoing clinical studies. Recently completed phase
III clinical trials of an idiotype protein vaccine suggest that the vaccine may have clinical
activity in a subset of patients. Efforts to enhance the efﬁcacy of active immunotherapy are
ongoing with an emphasis on optimization of antigen delivery and presentation of vaccines
and modulation of the immune system toward counteracting immunosuppression, using
antibodies against immune regulatory checkpoints. This article discusses results of the
various immunotherapy approaches applied to date for B-cell lymphoma and the ongoing
trials to improve their effect.
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INTRODUCTION
Indolent non-Hodgkin’s lymphomas (NHL), themost commonof
which is follicular lymphoma (FL), remain incurable. Therefore,
new therapeutic modalities that target tumor cells more speciﬁ-
cally and with less toxicity are needed. Targeted immunotherapy
ideally ﬁts these two requirements, hence both passive and active
immunotherapies are widely studied.
Passive immunotherapy based on monoclonal antibodies
(mAbs) has already improved the clinical outcome in lymphoma.
The anti-CD20 mAb rituximab is presently utilized as a standard
of care for lymphoma. However, although rituximab signiﬁcantly
improves duration of remissions and overall survival (Czuczman
et al., 2004; Fisher et al., 2005a; Hiddemann et al., 2005), patients
eventually relapse from residual tumor cells and die of the disease.
Newer generations of improved antibodies are therefore awaited.
Active immunotherapy trials so far consist largely on vac-
cines that use the immunoglobulin idiotype (Id) as a tumor-
speciﬁc antigen. Each B lymphocyte expresses on its surface an
immunoglobulin molecule, capable of recognizing and bind-
ing to a unique antigen. The Id refers to the unique amino
acid sequences within the complementarity determining regions
(CDR) in the variable regions of the immunoglobulin heavy and
light chains. The entire immunoglobulin with its unique variable
regions is commonly referred to as the Id protein. Since B-cell
lymphomas are clonal in nature, arising from a single B-cell,
their immunoglobulin Id is distinct from the Id expressed by
their non-malignant counterparts. Therefore, the Id is regarded
as a tumor-speciﬁc antigen that can be targeted by immunother-
apy. Unlike passive immunotherapy, regulatory approval has not
yet been granted to any regimen of active immunotherapy for
lymphoma, despite evidence of biological and clinical efﬁcacy as
well as clinical beneﬁt of Id vaccination in lymphoma patients
(Bendandi et al., 1999; Inoges et al., 2006; Schuster et al., 2011).
Further trials of vaccines as well as immune checkpoint blockade
are ongoing.
This review describes current immunotherapy approaches for
B-cell lymphoma and discusses the ongoing efforts and prospects
for their improvement.
PASSIVE IMMUNOTHERAPY BY ANTIBODIES
The ﬁrst antibody-based therapy for B-cell lymphoma utilized
anti-Id mAbs. Although these antibodies were eventually aban-
doned because they need to be tailored for each patient, they
provided evidence that antibody-based therapy can be safe and
highly effective (Miller et al., 1982), paving the way for subsequent
development of the anti-CD20 mAb rituximab.
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ANTI-CD20 ANTIBODIES
Rituximab, a human–mouse chimeric IgG1 antibody that targets
CD20 revolutionized the treatment of FL and is now a standard
component of ﬁrst-line therapy. As a single agent or in combi-
nation with chemotherapy it improves the overall response rate
(ORR), the duration of response and overall survival (Czuczman
et al., 2004; Fisher et al., 2005a; Hiddemann et al., 2005).
Mechanisms of action of rituximab
Rituximab depletes both normal and malignant B-cells. Four
major mechanisms have been proposed for the action of rit-
uximab: antibody-dependent cellular cytotoxicity (ADCC) and
phagocytosis, complement-dependent cytotoxicity (CDC), direct
induction of apoptosis, and “vaccination effect” resulting from
cross-priming (Glennie et al., 2007; Rezvani and Maloney, 2011).
These mechanisms have been demonstrated in vitro and in mouse
models, and clinical observations support their activity in patients.
However, their relative contribution to the overall clinical effect
remains unclear. The controversy regarding the relative contribu-
tion of each mechanism originates at least in part from the use
of different anti-CD20 mAbs and different experimental models.
Anti-CD20 mAbs are divided into two subtypes based on their
functional activity upon antigen ligation. Type I anti-CD20 mAbs,
such as rituximab, redistribute CD20 into membrane lipid rafts
and potently activate complement, whereas type II anti-CD20
mAbs that do not redistribute CD20 are weak complement activa-
tors but potent inducers of programmed cell death (PCD). Both
subtypes are equal in their ability to activate Fcγ receptor (FcγR)-
bearing effector cells (Chan et al., 2003; Cragg et al., 2003; Glennie
et al., 2007).
Growing evidence indicates that recruitment of innate effector
cells via Fc/FcγR interaction is critical to the therapeutic efﬁcacy
of rituximab. In mouse models, depletion of both normal and
malignant B-cells by anti-CD20 mAbs was dependent on active
FcγRs (Uchida et al., 2004; Minard-Colin et al., 2008). In the clin-
ical setting, FL patients who carry the genetic polymorphism 158
V/V that codes for a high afﬁnity FcγRIIIa show higher response
rates to rituximab as compared to patients with low afﬁnity poly-
morphisms (158 V/F or 158 F/F; Koene et al., 1997; Cartron
et al., 2002; Weng and Levy, 2003), supporting an important
role for ADCC. In chronic lymphocytic leukemia (CLL) however,
FcγR polymorphisms failed to predict the response to rituximab
(Farag et al., 2004), suggesting that mechanisms of tumor clear-
ance independent of Fc/FcγR interactions may be more important
in CLL. It should be noted that although natural killer (NK)
cells, macrophages, and neutrophils have been implicated in the
elimination of B-cells by anti-CD20 antibodies, the nature of the
critical effector cells responsible for the therapeutic effect remains
disputed.
Complement-dependent cytotoxicity may represent another
effector mechanism, although the role of complement remains
controversial. In some murine models of lymphoma, rituximab
effectively destroyed tumor cells in mice with a functioning
complement system but its activity was ablated in complement-
deﬁcient mice (Di Gaetano et al., 2003; Golay et al., 2006). How-
ever, other studies showed no requirement for complement in
the depletion of normal B-cells using C1q-, C3-, and C4-deﬁcient
mice (Uchida et al., 2004; Hamaguchi et al., 2005). A number of
factors may account for the controversy regarding the involvement
of CDC in anti-CD20 antibody immunotherapy. One major fac-
tor is the type of tumor, as many tumors are protected from CDC
by complement defense molecules. In addition, the microenviron-
ment may play a role in the sensitivity of cells to CDC. Thus, it
has been demonstrated that unlike circulating cells, B-cells in the
marginal zone compartment exhibit dependency on complement
for anti-CD20 antibody killing (Gong et al., 2005). Tumor bur-
den is another factor that may determine the mechanism of action
of anti-CD20 mAbs. It has been recently reported that while low
tumor load can be eliminated by complement alone, elimination
of high tumor load requires multiple effector mechanisms (Boross
et al., 2011). In humans, there is evidence that complement is
activated by rituximab. Thus, rituximab infusion results in rapid
depletion of complement components due to their consumption
(Kennedy et al., 2004). However, some studies point to deleteri-
ous rather than therapeutic effects of complement activation. In
fact, some of the side effects of rituximab treatment have been
ascribed to complement activation (van der Kolk et al., 2001).
In addition, blockade of ADCC by deposited C3b complement
component has been demonstrated (Wang et al., 2008). Moreover,
FL patients with a C1qA polymorphism associated with low C1q
levels showed correlation with prolonged response to rituximab
(Racila et al., 2008). Therefore, the involvement of complement in
anti-CD20 therapy, particularly its suggested detrimental role, has
to be further substantiated.
A third proposed mechanism of action of rituximab is direct
cell killing through signaling. Binding of rituximab has been
shown to induce PCD in vitro in several B-cell lines (Hofmeis-
ter et al., 2000; Shan et al., 2000). The PCD was dependent on
crosslinking of rituximab, which is believed to be mediated in vivo
through FcγR-bearing cells. The in vitro ﬁndings were supported
by the demonstration that rituximab induces caspase activation
in CLL patients, which correlates with tumor cell depletion (Byrd
et al., 2002). In contrast, many other B-cell lines appear insen-
sitive to direct killing in vitro, and de Haij et al. (2010) showed
in a mouse model that Fc-dependent crosslinking of antigen–
antibody immune complexes is insufﬁcient for the therapeutic
activity in vivo. Hence, the ability of anti-CD20 mAbs to induce
cell death through signaling remains controversial.
“Vaccination” by cross-priming has more recently been sug-
gested as an additional mechanism of action. The concept of
cross-priming implies that following antibody-induced apopto-
sis, cell debris are taken up by antigen presenting cells and then
presented to cytotoxic T lymphocytes speciﬁc for lymphoma-
associated antigens. Such an adaptive immune induction by
CD20 antibodiesmay underlie the durable remissions experienced
by some rituximab-treated patients (Hainsworth et al., 2002).
Although cross-priming induced by rituximab has been demon-
strated in vitro (Selenko et al., 2001), its occurrence in vivo remains
uncertain. However, several studies support a role for a “vaccine
effect.” Thus, treatment of immunocompetent mice with anti-
CD20 mAb induces T-cell-mediated protection against human
CD20-expressing tumor cells (Abes et al., 2010), and anti-CD20
mAb treatment synergizes with dendritic cell (DC) vaccination in
the therapy of established murine lymphoma (Gadri et al., 2009).
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Moreover, a clinical study demonstrated that rituximab therapy
induces an Id-speciﬁc T-cell response in FL patients (Hilchey et al.,
2009). It is hoped that future studies will offer a decisive answer as
to the importance of this mechanism.
Rituximab resistance
Despite being the most successful anti-cancer mAb to date, the
effectiveness of rituximab is ultimately limited due to develop-
ment of resistancewith relapse of the disease. Rituximab resistance
is mediated by both tumor and host factors. Lymphoma cells may
develop resistance because of increased expression of complement
regulatory proteins that impair CDC (Takei et al., 2006), block-
ade of ADCC by deposited C3b complement component (Wang
et al., 2008), overexpression of anti-apoptotic proteins or down-
regulation of pro-apoptotic proteins (Olejniczak et al., 2008), and
down-regulation of CD20 either through loss of expression (Davis
et al., 1999), shaving of rituximab/CD20 complexes by phago-
cytic cells (Beum et al., 2006), or antigenic modulation through
internalization that has been previously believed to be of little sig-
niﬁcance (Beers et al., 2010). Host-related resistance is mediated
by exhaustion of complement components (Kennedy et al., 2004;
Klepﬁsh et al., 2008) or effector cells (Berdeja et al., 2007). The
relative contribution of these mechanisms to rituximab resistance
remains to be determined in further clinical studies.
Prospective improvement of anti-CD20 antibody therapy
Understanding the mechanisms of rituximab action and resis-
tance are critical for the development of strategies to improve
the clinical outcome of anti-CD20 antibody therapy. Based on
present knowledge, two strategies are being investigated: improve-
ment of rituximab efﬁcacy and development of newer generation
anti-CD20 mAbs.
Improvement of rituximab efﬁcacy. Enhancing sensitivity of
lymphoma cells to rituximab is one approach to improve its efﬁ-
cacy. Rituximab-resistant lymphoma cells exhibit up-regulation
of components of the ubiquitin–proteasome system. Of several
proteasome inhibitors that have been shown in vitro to sensitize
lymphoma cells to rituximab, bortezomib has entered clinical tri-
als. Following a phase II trial showing that the combination of
bortezomib with rituximab is feasible as a salvage treatment in
relapsed or refractory indolent lymphomas (de Vos et al., 2009), a
phase III trial is ongoing. Similarly, since anti-apoptotic proteins
of the Bcl-2 family have been implicated in rituximab resistance,
Bcl-2 inhibitors such as the antisense oligonucleotide oblimersen
are investigated. A phase II study combining oblimersen with
rituximab resulted in a promising response rate of 60% in FL
patients, some of which were refractory to prior treatment with
rituximab (Pro et al., 2008). Results of larger randomized trials in
rituximab-resistant patients are awaited.
Enhancement of ADCC is another potential approach to
improve rituximab efﬁcacy. Along this line, several cytokines have
been combined with rituximab to boost ADCC. Disappointingly,
response rates to the combination treatment were not signiﬁ-
cantly different from those obtained with rituximab alone. For
instance, in a phase II study of rituximab combined with IL-2 in
rituximab-refractory indolent NHL, no clinical responses could
be demonstrated although the IL-2 expanded FcR-bearing cells
in vivo and enhanced in vitro ADCC (Khan et al., 2006). When G-
CSF was combined with rituximab in CLL, ORR was comparable
to that seen with rituximab monotherapy. Interestingly, remission
duration was remarkably long (van der Kolk et al., 2003; Gruber
et al., 2011). This ﬁnding should be substantiated in further trials.
Agents other than cytokines have been also investigated as adjuncts
to rituximab to enhance ADCC. The toll-like receptor 9 (TLR9)
agonist CpG oligonucleotide (ODN) has been combined with rit-
uximab in a phase II study in patients with relapsed or refractory
FL (Friedberg et al., 2009a). Clinical responses were observed in
48%of patients despite adverse prognostic factors,warranting fur-
ther studies. Noteworthy, a recent preclinical study suggests that
TLR3 agonists may be preferred agents for enhancing CD20 mAb
efﬁcacy (Horikawa et al., 2011). According to this study, a rare IL-
10 producing regulatory B-cell subset that is not entirely depleted
by anti-CD20 mAbs (B10 cells) inhibits lymphoma depletion dur-
ing immunotherapy. In contrast to TLR9 agonists, TLR3 agonists
do not activate B10 cells hence enhance lymphomadepletionmore
effectively. Although poly(I:C) is not used clinically because of its
toxicity, poly(I:C)-like agents are available for clinical use (Ambrus
et al., 2006).
While the contribution of complement to the therapeutic efﬁ-
cacy of rituximab remains controversial, strategies to overcome
complement resistance and enhance CDC are being investigated.
Since rituximab resistance is associated with up-regulation of
membrane complement regulatory proteins, their blocking may
enhance rituximab efﬁcacy.Neutralizing antibodies abrogating the
function of CD55 and CD59 markedly enhanced the antitumor
activity of rituximab in vitro and in vivo in immunodeﬁcient mice
(Macor et al., 2007). Similarly, knockdown of CD55 expression
using siRNA attenuated the resistance of NHL cells (clinical sam-
ples) to CDC activated by rituximab (Terui et al., 2006). Another
target for siRNA is mortalin, the mitochondrial hsp70 involved in
complement resistance. In vitro experiments showed thatmortalin
silencing in human B-cell lymphoma sensitized the cells to com-
plement attack by rituximab (Masarwa et al., 2008). It is therefore
assumed that combination of rituximab with agents that block
complement regulatory pathways may enhance tumor cell killing.
None of these approaches has yet reached clinical trials. However,
the in vivo application of siRNA and antisense oligonucleotides is
a rapidly developing and promising ﬁeld.
Additionally, repletion of depleted complement components by
infusion of fresh frozen plasma has been tested in CLL patients as
a means to overcome rituximab resistance (Klepﬁsh et al., 2008;
Xu et al., 2010). These results remain to be conﬁrmed in con-
trolled trials. It should however be kept in mind that complement
activation by rituximab may act as a double edged sword, hence
extensive complement supply may not be desirable.
New generation anti-CD20 mAbs. Several new generation
anti-CD20 mAbs are currently undergoing clinical investigation
(Table 1). These mAbs are humanized or fully human, unlike the
chimeric rituximab. Their design was based on current insights
into the mechanisms of rituximab action and resistance aiming
at improving their functions, including greater antibody-target
binding, enhanced FcRγ binding, enhanced CDC and PCD. It
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Table 1 | New generation anti-CD20 mAbs in clinical development.
Antibody Characteristics Activity compared with rituximab Phase of development
Ofatumumab Type I, fully human Increased CDC and slower off-rate FDA approved for CLL and phase III trials in NHL
Veltuzumab Type I, humanized Slower off-rate Phase I/II of subcutaneous administration in NHL
and CLL
Ocrelizumab Type I, humanized Increased ADCC and lower CDC Phase II in NHL
PR0131921 Type I, humanized with modiﬁed Fc Increased ADCC Phase I/II in NHL
AME-133v Type I, humanized with modiﬁed Fc Increased ADCC Phase I/II in NHL
GA101 Type II, humanized with glyco-engineered Fc Increased ADCC and direct PCD Phase III in NHL and in DLBCL
remains to be determined whether they are doing better compared
to rituximab in naïve patients and whether they show therapeutic
activity in rituximab-refractory patients.
Among the new generation mAbs, ofatumumab is at the most
advanced-stage of clinical development. It is a fully human type
I mAb that binds a unique epitope in the small extracellular loop
of the CD20 molecule, which is in close proximity of the cell
membrane. Antibody binding to this epitope results in a slow
off-rate and an exceptionally high ability to recruit C1q and
lyse cells through complement activation (Teeling et al., 2006).
Ofatumumab induces CDC in vitro in a range of rituximab-
resistant cells (Teeling et al., 2004). Importantly, ofatumumab
showed toxicity proﬁle similar to that of rituximab, indicating
that the increased ability of ofatumumab to activate complement
does not further increase toxicity (Coifﬁer et al., 2008; Hagen-
beek et al., 2008). A phase I/II clinical trial with ofatumumab
in relapsed/refractory FL patients showed encouraging ORR of
42% (Hagenbeek et al., 2008). However, a subsequent study on
heavily pre-treated patients with rituximab-resistant FL showed
disappointing ORR of 11% (Hagenbeek et al., 2009), suggest-
ing that ofatumumab monotherapy is ineffective in rituximab-
refractory FL. The mAb may however be of beneﬁt in combi-
nation with chemotherapy. Studies of ofatumumab combined
with CHOP chemotherapy in patients with FL are ongoing
(NCT00494780). According to an early report, ofatumumab was
highly effective in combination with CHOP chemotherapy in
previously untreated FL patients (van Meerten and Hagenbeek,
2011). The mAb appears to be more effective in CLL than in FL
(Wierda et al., 2010a).Ofatumumabmonotherapy resulted in high
response rates in patients with ﬂudarabine–alemtuzumab refrac-
tory CLL (58% ORR) and patients with bulky ﬂudarabine refrac-
toryCLL (47%ORR). Retrospective analysis of the treated patients
revealed that ofatumumab was active in ﬂudarabine refractory
CLL irrespective of prior rituximab. ORR for rituximab-treated,
rituximab-refractory, and rituximab-naïve patients was 43, 44,
and 53% (Wierda et al., 2011). In 2009 ofatumumab received
FDA approval for use in ﬂudarabine and alemtuzumab refrac-
tory CLL. Yet, it is important to bear in mind that much higher
doses of ofatumumab were administered than previously used for
rituximab.
Veltuzumab is a humanized type I mAb with CDRs identi-
cal to rituximab except for a single amino acid substitution in
CDR3-VH, which translates into a slower dissociation rate. When
compared with rituximab, veltuzumab showed greater antitu-
mor activity in murine models and greater B-cell depletion in
cynomolgus monkeys (Goldenberg et al., 2009). In a phase I/II
clinical trial, veltuzumab appeared safe and the ORR to single
agent veltuzumab was 44% in patients with relapsed/recurrent FL,
which is comparable with that of rituximab in a similar patient
population (Morschhauser et al., 2009). Importantly, veltuzumab
was active when injected subcutaneously and at doses lower than
the standard dose of rituximab, properties that warrant further
studies and are currently being investigated in NHL and CLL
(NCT00546793).
Ocrelizumab is a humanized type I anti-CD20 mAb that differs
from rituximab at several positions within the CDRs. Compared
with rituximab, ocrelizumab demonstrated superior binding to
low afﬁnity FcγRIIIa variants, increased ADCC, and lower CDC.
In a phase I/II trial in patients with relapsed/refractory FL after
prior rituximab therapy, ORR was 38% with apparently milder
adverse events, probably due to decreased complement activa-
tion (Morschhauser et al., 2010a). These results are in the range
of rituximab re-treatment. The clinical development of ocre-
lizumab was suspended in 2010 following excess death rates of
opportunistic infections in lupus erythematosis and rheuma-
toid arthritis, although studies are ongoing in multiple sclerosis.
As for CD20-positive malignancies, there has been little further
development.
Third-generation type I humanized anti-CD20 mAbs, such as
PRO131921 and AME-133v, are mAbs in which the Fc fragment
was modiﬁed to increase its afﬁnity to FcγRIIIa and thus enhance
ADCC. In preclinical studies, these mAbs had superior activity
compared to rituximab (Bowels et al., 2006). In phase I trials,
PRO131921 and AME-133v showed clinical activity in rituximab-
pre-treated relapsed FL (Friedberg et al., 2009b; Tobinai et al.,
2011). AME-133v is currently undergoing a phase I/II trial in
relapsed/refractory FL (NCT00354926).
Unlike other ani-CD20 mAbs in clinical development, the
third-generation GA101 is a type II antibody. It has a glyco-
engineered Fc fragment with non-fucosylated oligosaccharides
to enhance the afﬁnity to FcγR, particularly FcγRIIIa, therefore
enhance ADCC (Mössner et al., 2010). Being a type II anti-CD20
mAb, GA101 induces effective direct and immune cell-mediated
cell killing. In preclinical models, GA101 was signiﬁcantly more
effective than rituximab inB-cell depletion and in tumor rejection.
Preliminary results of a phase I/II study showed that GA101 as a
single agent has a similar safety proﬁle to rituximab and a promis-
ing efﬁcacy (ORR of 58%) in patients with relapsed/refractory B-
NHL (mainly FL) who previously received rituximab (Salles et al.,
2008). Phase III trials of GA101 combined with chemotherapy
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have been initiated in previously untreated diffuse largeB-cell lym-
phoma (DLBCL; NCT01287741) and rituximab-refractory indo-
lent NHL (NCT01059630). Clinical data of this promising agent
are awaited.
CD20 antibody radio conjugates. Radio immunotherapy has
emerged as a promising treatment option for lymphoma. Two
radio conjugates of anti-CD20 mAbs are currently approved
by the FDA: 131I-tositumomab (Bexxar) and 90Y-ibritumomab
tiutexan (Zevalin). Both of them have demonstrated high clin-
ical efﬁcacy in heavily pre-treated patients, including patients
with chemotherapy- and rituximab-refractory disease with poor
prognostic characteristics. Thus, in ﬁve clinical trials, patients
with indolent NHL that were treated with one course of 131I-
tositumomab demonstrated ORR ranging from 47 to 68% with
complete response (CR) rates ranging between 20 and 38% (Fisher
et al., 2005b). The 5-year progression-free survival (PFS) was
17% with a median follow-up of 5.3 years. Eighty-one (32%) of
250 patients had a long-term durable response (PFS greater than
1 year), and the median duration of response for those patients
was 45.8months. Similar durable responses were observed in 90Y-
ibritumomab tiuxetan-treated patients with relapsed/refractory
NHL (Witzig et al., 2007). In four clinical trials, 59 (39%) of 153
patients with indolent FL had a long-term response (PFS of more
than 1 year), and the median time to progression was 30.9months.
Radioimmunotherapy has also demonstrated excellent
response rates in the front-line treatment of previously untreated
advanced-stage indolent FL, either as a single agent or in combi-
nation with chemotherapy. Kaminski et al. (2005) reported that
treatment with 131I-tositumomab as single agent in 76 patients
with stage III or IV FL resulted in ORR of 95%, with a CR rate
of 74%. The 5-year PFS for all patients was 59%, and the median
PFS was 6.1 years with a median follow-up of 5.1 years. In a phase
II trial of CHOP chemotherapy followed by 131I-tositumomab
for previously untreated FL, the ORR was 91% including a 69%
CR rate. After a median follow-up time of 5.1 years, the 5-year
ORR was 87%, and the PFS rate was 67% (Press et al., 2006).
This outcome was superior to historical ﬁgures of patients treated
with CHOP alone, which led to phase III randomized trial of
CHOP plus rituximab versus CHOP plus 131I-tositumomab in
newly diagnosed NHL (NCT00006721). The study is ongoing and
results are eagerly awaited. Another randomized phase III trial
to evaluate the efﬁcacy of consolidation with 90Y-ibritumomab
tiuxetan in patients with advanced-stage FL in ﬁrst remission was
already completed and published (Morschhauser et al., 2008). 90Y-
ibritumomab tiuxetan consolidation signiﬁcantly prolonged the
median PFS by 2 years in all patients regardless of whether patients
achieved partial response (PR) or CR after induction treatment.
After 90Y-ibritumomab tiuxetan consolidation, 77% of patients in
PR after induction converted to CR, resulting in a ﬁnal CR rate
of 87%.
Altogether, there is substantial evidence demonstrating that
radioimmunotherapy is extremely effective. However, this treat-
ment modality is not yet widely applied. Favorable awaited results
of ongoing trials in patients with indolent NHL and in patients
with more aggressive lymphomas may speed its adoption in the
clinic.
TARGETING OTHER LYMPHOMA ANTIGENS
Although mAbs to CD20 dominate clinical studies in lymphoma,
mAbs to other antigens are being developed (Table 2). Antibod-
ies with activity that warrants further development are brieﬂy
reviewed.
CD22
CD22 is a B-cell restricted surface molecule involved in regulation
of B-cell activation. Epratuzumab is a humanized anti-CD22 mAb
that has shown only modest single agent activity in pre-treated FL
(Leonard et al., 2003). However, the combination of epratuzumab
with rituximab demonstrated enhanced anti-lymphoma activity
compared with either mAb alone. A phase II trial, evaluating the
combination of epratuzumab and rituximab in patients with dif-
ferent types of refractory/relapsedNHL showedORRof 47%,with
the best responses being observed in patients with FL and DLBCL
(64%; Strauss et al., 2006). In another phase II study, the com-
bination of epratuzumab, rituximab, and CHOP chemotherapy
in previously untreated DLBCL provided ORR of 96% (Micallef
et al., 2011). These results led to the production of anti-CD20/anti-
CD22 bispeciﬁc mAbs (Rossi et al., 2009). The rationale was that
crosslinking of the two target molecules by bispeciﬁc antibodies
may have therapeutic advantage over the combination of the two
parental mAbs, an assumption that needs to be veriﬁed in clinical
studies.
Epratuzumab has been also applied as an antibody radio conju-
gate. In a phase I/II study in patientswith relapsed/refractoryNHL,
treatment with 90Y-epratuzumab tetraxetan demonstrated ORR
and median PFS of 62% (CR48%) and 9.5months, respectively
(Morschhauser et al., 2010b).
Inotuzumab ozogamicin (CMC-544) is a mAb-drug conjugate
composed of a humanized anti-CD22 mAb linked to the potent
cytotoxic agent calicheamicin. In two studies of patients with
relapsed/refractory FL and DLBCL who were treated with ino-
tuzumab ozogamicin alone or in combination with rituximab, the
response rates and PFS results indicated promising efﬁcacy, albeit
not as impressive in rituximab-refractory patients (Dang et al.,
2009; Advani et al., 2010). These results support continued clinical
development of this regimen.
CD30
CD30 is a pro-survival receptor expressed on Reed Sternberg cells
of Hodgkin’s lymphoma (HL) and on anaplastic large-cell lym-
phoma. Several mAbs have been developed against CD30 includ-
ing SGN-30, MDX-060, MDX-1401, and XmAb2513. Despite
promising results in preclinical studies, early clinical studies
with naked anti-CD30 mAbs demonstrated minimal activity. In
contrast, the drug conjugate Brentuximab vedotin (SGN-35), a
chimeric anti-CD30 mAb combined with the antimitotic agent
vedotin, has shown highly promising clinical efﬁcacy. In a pilot
phase I study, brentuximab vedotin was administered to 45
patients with relapsed or refractory CD30-positive malignancies,
primarily HL (Younes et al., 2010). Objective responses, includ-
ing 11 complete remissions, were observed in 17 patients. The
median duration of response was at least 9.7months. Tumor
regression was observed in 36 of 42 patients who could be
evaluated (86%). This is an excellent result for a single agent
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Table 2 | Clinical development of mAbs against antigens other than CD20.
Antibody Target Characteristics Phase of development
Epratuzumab CD22 Humanized anti-CD22 mAb Phase II in NHL
Inotuzumab ozogamicin CD22 Humanized anti-CD22 mAb conjugated with calicheamicin Phase I/II in NHL
90Y-epratuzumab tetraxetan CD22 Humanized anti-CD22 mAb conjugated with90Y Phase I/II in NHL
Brentuximab vedotin CD30 Chimeric anti-CD30 mAb conjugated with vedotin Phase II in HL
Lucatumumab CD40 Fully human anti-CD40 mAb Phase I/II in NHL and HL
Alemtuzumab CD52 Humanized anti-CD52 mAb FDA approved for resistant CLL, phase III as
ﬁrst-line in CLL, phase II in DLBCL
Blinatumomab CD19/CD3 Anti-CD19/anti-CD3 BiTE (bispeciﬁc T-cell engager) Phase I in NHL
treatment in heavily pre-treated refractory HL. Based on these
results, a phase II trial of brentuximab vedotin in patients with
relapsed/refractory HL is ongoing (NCT00848926) and results are
eagerly awaited.
CD40
Agonistic mAbs to CD40 may be particularly effective due to stim-
ulation of host antitumor immune responses. Two anti-CD40
mAbs have been investigated. Dacetuzumab (SGN-40), a human-
ized mAb, failed to demonstrate clinical efﬁcacy in phase I/II
trials and its development was therefore discontinued. Lucatu-
mumab (HCD122), a fully human mAb, is currently investigated
in a phase I/II study in progressive NHL and HL after at least
two prior therapies (NCT00670592). In addition, a phase I study
of lucatumumab and bendamustine combination in rituximab-
refractory FL is ongoing (NCT01275209). In regard to the limited
clinical efﬁcacy of agonistic CD40 mAbs, it has been recently
demonstrated that co-engagement of the Fc domain of agonistic
CD40 mAbs with the inhibitory FcγRIIB is required for CD40-
mediated immune activation and antitumor activity (Fubin and
Ravetch, 2011). This unexpected ﬁnding has direct implication for
immunotherapy. Thus, the design of agonistic CD40 mAbs with
increased binding afﬁnity to FcγRIIB may enhance their clinical
efﬁcacy.
CD52
CD52 is expressed onmost lymphoidmalignancies.Alemtuzumab
(Campath-1H), a humanized anti-CD52 mAb, is approved by
the FDA for the treatment of ﬂudarabine-resistant CLL. Also, as
demonstrated in a phase III study in CLL patients, ﬁrst-line treat-
ment with alemtuzumab resulted in signiﬁcantly improved PFS,
ORR, and CR compared with chlorambucil (Hillmen et al., 2007).
A phase II trial of alemtuzumab and dose-adjusted EPOCH–
Rituximab in relapsed or refractory DLBCL is currently ongoing
(NCT01030900).
CD19
CD19, a B-cell restricted membrane glycoprotein involved in
regulation of B-cell activation, was one of the ﬁrst targets for
immunotherapy by naked mAbs and by immunotoxins. How-
ever, because clinical efﬁcacy of anti-CD19 mAbs was mod-
est and because anti-CD20 mAbs emerged as more promising
agents, the development of anti-CD19 mAb therapy has been
halted. Nonetheless, promising results have been obtained with
the bispeciﬁc T-cell engaging (BiTE) blinatumomab (MT103), a
CD19×CD3 bispeciﬁc single chain antibody that recruits effec-
tor T-cells to lymphoma cells, resulting in effective tumor cell
killing (Bargou et al., 2008). Doses as low as 0.005mg/m2/day
in NHL patients led to elimination of target cells in blood. Par-
tial and complete tumor regressions were ﬁrst observed at a dose
level of 0.015mg, and all seven patients treated at a dose level
of 0.06mg experienced tumor regression. Ongoing studies (Viar-
dot et al., 2010) suggest that T-cell engaging antibodies appear
to have a promising therapeutic potential that warrants further
development.
ACTIVE IMMUNOTHERAPY
As opposed to passive immunotherapy with mAbs, active
immunotherapy may induce a polyclonal response directed
against multiple epitopes, hence limiting tumor escape that gives
rise to relapse. In addition, active immunotherapy can induce
long-lasting antitumor immunity, thereby limiting the likeli-
hood of relapse. On the other hand, the disadvantage of active
immunotherapy is its reliance on the patient’s immune system,
which may be dysfunctional. Current clinical studies of active
immunotherapy for lymphoma consist largely of vaccination and
immune checkpoint blockade that will be herein reviewed.
VACCINATION
The most thoroughly studied target for vaccination in lymphoma
is the immunoglobulin Id. A major obstacle in production of
Id vaccines derives from its patient-speciﬁc nature that requires
the generation of a custom-made product. However, the manu-
facturing issues were overcome by advances in hybridoma and
recombinant DNA technology. The Id may be used as either pro-
tein or DNA in therapeutic vaccines. In the traditional rescue
hybridization technique, the Id protein is produced by fusing the
lymphoma cells withmousemyeloma cells to generate Id-secreting
hybridomas (Levy and Dilley, 1978). For recombinant Id protein
production, genes encoding the tumor-speciﬁc immunoglobulin
variable regions are cloned by polymerase chain reaction, ligated
into an expression vector and transfected into bacterial, plant,
insect, or mammalian cells that then produce the Id protein (Park
and Neelapu, 2008). For Id DNA vaccination, the immunoglobu-
lin heavy and light chains are cloned and inserted into a plasmid
vector for naked DNA injection.
Most clinical trials of Id vaccines for lymphoma have been per-
formed on patients with FL. One reason for this is the indolent
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nature of FL that gives time for the vaccine to be produced and for
the patient’s immune system to recover after aggressive chemother-
apy. In addition, FL is regarded as particularly immune responsive
based on occurrence of spontaneous regressions, high response
rates to mAb treatment, occasional responsiveness to interferon-α
and IL-2, and correlation of survival time with gene expression
proﬁle of tumor inﬁltrating immune cells (Hollander, 2009).
Id protein vaccines
The native Id is a weak immunogen. However, it can be made
immunogenic by coupling it to a carrier protein and by admin-
istering it with an immunologic adjuvant. Based on preclinical
and early clinical studies, the most widely used Id protein vaccine
formulation consists of the Id protein coupled to the powerful
immunogenic keyhole limpet hemocyanin (KLH) with the addi-
tion of granulocyte–macrophage colony-stimulating factor (GM-
CSF), which facilitates induction of tumor-speciﬁc CD8 T-cells
(Bendandi et al., 1999).
Phase I/II clinical trials. Several early phase trials of Id–KLH
plus GM-CSF vaccines in FL have demonstrated promising clin-
ical responses and clinical beneﬁt. Bendandi et al. (1999) con-
ducted a phase I/II clinical trial in which 20 FL patients in
ﬁrst chemotherapy-induced complete remission received an Id–
KLH+GM-CSF vaccine. Despite being in complete remission,
all 11 patients with detectable t (14; 18) chromosomal transloca-
tions in their primary tumors had cells from the malignant clone
detectable in the blood by PCR. However, 8 of 11 patients showed
complete elimination of residual tumor cells (detectable by PCR)
immediately after completing vaccination and sustained theirmol-
ecular remissions for a median of 18months. Tumor-speciﬁc CD8
andCD4T-cellswere found in19out of 20patients (95%),whereas
anti-Id antibodies were detected in 15 out of 20 patients (75%).
Vaccination was thus associated with clearance of residual tumor
cells from blood and long-term disease-free survival. In another
phase I/II study, 22 patients in ﬁrst remission after chemother-
apy were immunized with Id protein conjugated to KLH and
administered with GM-CSF. Among 21 evaluable patients, 62%
mounted Id-speciﬁc immune responses. At median follow-up of
more than 6 years,median PFS was 38months (Timmerman et al.,
2009).
Clinical trials were performed not only in patients in ﬁrst
chemotherapy-induced remission. In a phase II study, 25 patients
received an Id–KLH plus GM-CSF vaccine following second
chemotherapy-induced complete remission (Inoges et al., 2006).
Twenty patients (80%) had either humoral or cellular Id-speciﬁc
immune responses. Themedian duration of the secondCR among
the 20 immune responders was signiﬁcantly longer than the
median duration of their ﬁrst CR or the chemotherapy-induced
second response. This trial conﬁrmed that Id vaccination induced
a speciﬁc immune response in the majority of patients with FL
and that speciﬁc immune responses were associated with a highly
signiﬁcant increase in disease-free survival.
Although the majority of early phase vaccination studies were
conducted in patients who were in complete remission or very
good partial remission after cytoreductive therapy, some stud-
ies evaluated vaccination of patients with previously treated
measurable disease. One such phase II trial in patients with mea-
surable disease demonstrated that Id–KLH plus GM-CSF vaccine
alone can induce tumor regression and durable clinical responses
(Redfern et al., 2006).
Phase III clinical trials. The encouraging results of the early
phase trials prompted initiation of three double-blind, random-
ized phase III clinical trials of Id vaccination after initial cytore-
ductive therapy (Table 3). Disappointingly, two of these studies,
sponsored by Genitope Inc., and Favrille Inc., found no statis-
tically signiﬁcant differences in PFS between the Id–KLH plus
GM-CSF vaccine and a control vaccine containing KLH plus GM-
CSF, although the vaccine was generally safe (Levy et al., 2008;
Freedman et al., 2009). Interestingly, the Genitope study demon-
strated a correlation of immune and clinical response with a
signiﬁcant difference in PFS among Id-vaccinated patients who
developed an anti-Id immune response compared to Id-vaccinated
patients who did not mount an immune response (40 versus
16months). This result suggests that a subgroup of patients may
beneﬁt from Id vaccination. The third phase III study, conducted
by NCI/Biovest International, demonstrated an improved disease-
free survival of 44.2months for patients in the experimental arm
versus 30.6months in the control arm (p = 0.045; Schuster et al.,
2011). This study is criticized because it was terminated before
completion of the planned accrual, resulting in a smaller sample
size than originally planned and a limited statistical power with an
inability to achieve the originally stipulated threshold of p< 0.01.
Several differences in trial design and vaccine formulation may
be responsible for the different clinical outcomes of the three phase
III trials. First, differences in patient eligibility seem to be impor-
tant. While the Biovest trial was limited to patients who were
in complete remission at the time of vaccination, the Genitope
and Favrille trials also included patients who achieved only PR
or even stable disease after chemotherapy. If these data are con-
ﬁrmed in future studies, it would strongly support the value of
vaccination in the minimal disease state. With this regard, a num-
ber of trials have already shown that Id vaccination can induce
immune responses after high-dose cytotoxic therapy and even
Table 3 | Phase III clinical trials of Id vaccination in follicular lymphoma.
NCI/biovest Genitope Favrille
Production of Id protein Hybridoma Recombinant Recombinant
Isotype of Id IgM or IgG IgG IgG
Pre-vaccine therapy PACE CVP Rituximab
Pre-vaccination status CR CR or PR CR, PR, or SD
Randomized patients 117 349 287
Primary endpoint DFS PFS TTP
Results p =0.047 NS NS
Reference Schuster et al.
(2011)
Levy et al.
(2008)
Freedman et al.
(2009)
CR, complete response; CVP, cyclophosphamide, vincristine, and prednisone;
DFS, disease-free survival; Id, idiotype; NS, not signiﬁcant; PACE, prednisone,
doxorubicin, cyclophosphamide, and etoposide; PFS, progression-free survival;
PR, partial response; SD, stable disease; TTP, time to progression.
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after myeloablative conditioning and bone marrow transplanta-
tion (Davis et al., 2001). Second, the Id protein in the Biovest
study was a hybridoma product, whereas the other two studies
used a recombinant Id, suggesting that manufacturing procedures
may be important. Third, the pre-vaccine therapy was different
in the three trials. Finally, the Id isotype may be of impor-
tance. While the Id isotype in the Biovest study was either IgM
or IgG, lymphomas in the other two studies were exclusively of
the IgG isotype. An intriguing ﬁnding in the Biovest study was
that among patients receiving an IgM-Id vaccine, median time to
relapse was 52.9 versus 28.7months in IgM isotype control-treated
patients (p = 0.001), while among patients receiving IgG-Id vac-
cine, median time to relapse was 35.1 versus 32.4months in IgG
tumor isotype control-treated patients (p = 0.87; Schuster et al.,
2011). If these data are validated, determination of Id isotype may
facilitate early identiﬁcation of patients who are more likely to
beneﬁt from vaccination.
Combination of Id vaccines and rituximab. The standard of
care for FL changed during the course of the three phase III
clinical trials and now includes the mAb rituximab. Because rit-
uximab depletes both normal and malignant B-cells, it is expected
to impair or delay the anti-Id humoral response in vaccinated
patients. Hence, it is crucial to determine its effects on Id-speciﬁc
T-cell responses. Neelapu et al. (2005) reported that vaccination
by Id–KLH plus GM-CSF in patients with mantle cell lymphoma
following rituximab-containing chemotherapy induced vigorous
CD4 and CD8 antitumor type I cytokine responses in the absence
of circulating B-cells. These results show that severe B-cell deple-
tion does not impair T-cell priming in humans, suggesting that Id
vaccines may be used in combination with rituximab. However,
vaccine boosts after B-cell recovery may be necessary for optimal
humoral responses.
Prospective improvement of Id vaccines.
Increasing Id immunogenicity, delivery, and presentation. Increas-
ing antigen immunogenicity, delivery, and presentation may
improve the clinical outcome of Id vaccines. Methods to improve
the immunogenicity of Id vaccines are being sought. The Id is cur-
rently chemically conjugated to KLH using glutaraldehyde. How-
ever, the extensive protein crosslinking via glutaraldehyde could
destroy immunogenic epitopes and inhibit proteolytic processing.
Therefore, to increase immunogenicity, milder chemical reagents
are tested. It has been demonstrated that a sulfhydryl-based Id-
carrier protein conjugation system using maleimide chemistry
enhanced the efﬁcacy of Id–KLH vaccines (Betting et al., 2008). In
addition, carriers more potent than KLH may be introduced. Sev-
eral bacterial products that have high immune-enhancing activity
and that can be linked to Id by chemical conjugation or by genetic
fusion have already been suggested (Neelson et al., 2008; Chen
et al., 2009).
Methods are also being sought for targeting antigen to anti-
gen presenting cells in order to enhance antigen uptake and
processing. Several cell surface receptors have been suggested as
potential targets. Targeting can be achieved for instance by link-
ing Id to the B subunit of E. coli heat labile toxin, which binds to
GM1 ganglioside receptors and facilitates antigen uptake through
receptor-mediated endocytosis (Chen et al., 2009). Antigen can
be also targeted to “scavenger” receptors such as the mannose
receptor, which binds to carbohydrate structures rich in termi-
nal mannose residues. In this regard, it is interesting to note that
recombinant proteins produced in insect cells are characterized
by terminal mannose residues. It has been reported that recombi-
nant insect cell-derived Id showedhigher binding to and activation
of DCs as well as enhanced immune stimulation, which involved
mannose receptor targeting (Betting et al., 2009).
Liposomes are widely accepted as effective carriers for vaccines.
Hence, incorporation of Id into cytokine-carrying liposomes has
been proposed as a means to enhance Id delivery. An early study
in FL patients demonstrated that delivery by a liposomal Id/IL-2
vaccine is safe, induces sustained tumor-speciﬁc CD4 and CD8
T-cell responses, and may therefore serve as a model for vaccine
development (Neelapu et al., 2004).
DNA vaccines. Idiotype DNA vaccines consist of a plasmid
encoding the immunoglobulin single chain variable fragment. The
DNA vaccine is injected into the skin or muscle, resulting in pro-
duction of the protein by the patient’s cells and presentation to the
immune system. Since this approach does not require in vitro pro-
duction of a puriﬁed protein, it is faster and less expensive. This is
particularly important in the case of a customized vaccine. Preclin-
ical studies showed that the Id DNA vaccine is not immunogenic
unless linked to a xenogeneic carrier (Syrengelas et al., 1996; King
et al., 1998). An early phase I/II study in FL patients immunized
with such a chimeric DNA vaccine was quite disappointing: only
1 out of 12 patients mounted an Id-speciﬁc immune response and
no clinical responsewas observed.To enhance the immunogenicity
of Id DNA vaccines, the Id was genetically fused to proinﬂamma-
tory chemokines such as MCP-3 and MIP-3α that target the Id
to DCs. These fusion vaccines enhance antigen uptake and pre-
sentation through chemokine receptor-mediated endocytosis and
exert a chemotaxis effect on DCs, thus enhancing anti-Id immune
responses (Biragyn et al., 1999). Preclinical studies in lymphoma
models demonstrated superior antitumor effects compared to an
Id–KLH protein vaccine.
The failure to translate the success of DNA vaccination in pre-
clinical models to the clinic is believed to be due to failure in
delivery of DNA. This failure reduced the initial enthusiasm.How-
ever, novel delivery systems such as electroporation dramatically
improve performance of DNA vaccination and are now in clinical
trials for several types of cancer (Stevenson et al., 2011).
DC vaccines. Dendritic cells loaded in vitro with antigen are
attractive vehicles for therapeutic cancer vaccines. In a pilot clin-
ical study, vaccination with autologous DCs pulsed ex vivo with
tumor-speciﬁc Id protein was examined in four patients with FL.
All patients developed antitumor cellular immune responses. In
addition, clinical responses have been observed with one patient
experiencing complete tumor regression, a second patient having
partial tumor regression, and a third patient resolving all evidence
of disease as detected by molecular analysis (Hsu et al., 1996). In
an extended trial with 35 patients, among 28 patients with residual
disease at the time of vaccination, 10 experienced tumor regression
(Timmerman et al., 2002). Randomized controlled clinical trials
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are required to deﬁnitively answer the question of clinical beneﬁt
induced by DC-based Id vaccination in lymphoma. This ﬁeld has
not progressed as anticipated, partly due to skepticism regarding
the feasibility and prospects of DC vaccines to gain regulatory
approval. The recent FDA approval of sipuleucel-T, a DC vaccine
against prostate cancer, provided a formal proof for the clinical
efﬁcacy of DC vaccines, and is likely to prompt development of
this therapeutic modality.
Combining Id vaccines with new adjuvants. Increasing evidence
argues that the success of an anti-cancer vaccine may rely on
immunoadjuvant stimulating effects. Hence, co-administration of
vaccines with various adjuvants is being evaluated for improv-
ing vaccine performance. One promising class of adjuvants with
potent immunostimulatory properties consists of CpG ODNs that
are capable of activating antigen presenting cells, B-cells, and NK
cells by engaging TLR9. B-cell malignancies are uniquely sensitive
to CpGODNs in that themalignant cells themselves express TLR9,
thus respond toCpGODNs by up-regulation of MHCand costim-
ulatory molecules, and by proliferation that can lead to activation
induced cell death (Weiner, 2009). Preclinical studies in animal
models showed that CpG ODN is a potent adjuvant when com-
binedwith vaccines (Liu et al., 1998).As discussed elsewhere in this
review, CpG ODN also demonstrates potent immunostimulatory
activity when combined with other therapeutic agents.
Tumor cell vaccines
One drawback of Id vaccination is the restriction of the antitumor
response to a single antigen. Therefore, vaccine formulations based
on autologous neoplastic cells have been investigated. These for-
mulations might potentially induce autoimmunity, but have the
advantage of widening the spectrum of target tumor-associated
antigens.
Unlike other malignant cells, B-lymphoma cells can be acti-
vated to express MHC class II and costimulatory cells, thus present
their own tumor-associated antigens and elicit T-cell responses.
Lymphoma cells are therefore excellent candidates for tumor cell-
based vaccination. One approach to activate malignant B-cells
is by ligation of CD40 via CD40–CD40 ligand (CD40L) inter-
action. This can be achieved either by mixing lymphoma cells
with CD40L expressing cells or by engineering lymphoma cells
to express CD40L. Following successful studies in animal mod-
els, this concept has been tested in patients with CLL. In phase
I trials, in which ex vivo CD40L-transduced autologous tumor
cells were reinfused to patients, reductions in leukemia cell counts
and lymph node size were seen (Wierda et al., 2000, 2010b). In
another phase I trial in CLL, in which patients received subcuta-
neous injections of autologous tumor cells transduced with both
CD40L and IL-2, three patients (30%) had>50% reduction in the
size of affected lymph nodes (Biagi et al., 2005), suggesting that
CD40-based immunotherapy may have clinical beneﬁt.
A vaccine formulation based on DCs loaded with killed tumor
cells rather than Id protein has also been studied. In a pilot study,
18 patients with relapsed and measurable indolent NHL were
injected subcutaneously with DCs loaded with tumor cells. The
vaccination achieved signiﬁcant objective clinical responses, and
was associated with signiﬁcant immune modulation (Di Nicola
et al., 2009). Six patients had objective clinical responses including
three continuous CR and three PR, with a median follow-up of
50.5months. Eight patients had stable disease, whereas four had
progressive disease.Clinical responseswere signiﬁcantly associated
with a reduction in regulatory T-cells (Treg) and maturation of
lymphocytes to the effector memory stage in either peripheral
blood or tumor specimen samples. These results indicate that
immunization of patients with tumor cell-loaded DCs represents
a potentially effective strategy for the treatment of indolent NHL
patients with measurable disease.
In situ vaccination
To circumvent the logistical difﬁculty of ex vivo manufacture of a
customized vaccine, an alternate approach of in situ vaccination
has been developed. It consists of low-dose irradiation to a sin-
gle lymphoma site, followed by intratumoral injection of CpG
at the same site. This maneuver kills some tumor cells at the
treated site, and the CpG activates nearby DCs, enhancing pre-
sentation of the released tumor antigens by the DCs. Residual
viable lymphoma cells can also be activated by CpG and present
the released antigens to T-cells. B-cell NHL are considered highly
suited to this maneuver because they are sensitive to radiotherapy
and because they express TLR9. Preclinical studies in a lymphoma
model indicated that the combination of local immunostimula-
tion and cytotoxic therapy was required to elicit powerful systemic
antitumor responses and tumor rejection (Li et al., 2007). In a
recent phase I/II study, 15 patients with low grade lymphoma were
treated by in situ vaccination (Brody et al., 2010). One patient had
a CR, three others had PR, and two patients had stable but contin-
ually regressing disease for periods signiﬁcantly longer than that
achieved with prior therapies. In situ vaccination induced tumor-
reactive memory CD8 T-cells. However, some patients’ tumors
were able to induce a suppressive, regulatory phenotype in autol-
ogous T-cells in vitro. These patients tended to have a shorter time
to disease progression. One clinically responding patient received
a second course of vaccination after relapse resulting in a sec-
ond,more rapid clinical response. These encouraging preliminary
resultswarrant further studyof CpG-based in situ vaccination.The
induction of tumor-reactive CD8 T-cells and inferior outcome
of patients with Treg-inducing tumors suggest that enhancing
T-effector cells and inhibiting Treg might further improve this
regimen of vaccination.
IMMUNE CHECKPOINT INTERVENTION
There is accumulating evidence that therapeutic vaccination is
enhanced by disruption of immunoregulatory pathways that limit
the magnitude and duration of the immune response. Although
most of the evidence comes from preclinical studies, several
approaches for immune checkpoint blockade have already been
tested in clinical trials for lymphoma patients.
Blockade of T-cell inhibitory signals
Anti-CTLA-4 mAb. Cytotoxic T-lymphocyte antigen 4 (CTLA-
4), a member of the CD28 family, is a key negative regulator of
T-cell activation. It is inducibly expressed in conventional T-cells
after activation and constitutively expressed in Treg. Blockade of
CTLA-4 by mAbs enhanced T-cell activation, improved immune
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responsiveness to anti-cancer vaccines in preclinical studies, and
had clinical activity against several types of cancer (Peggs et al.,
2008). Following a phase III trial, demonstrating overall survival
beneﬁt in metastatic melanoma, the anti-CTLA-4 human mAb
ipilimumab was approved by the FDA in 2011 to treat patients
with late-stage melanoma. Ipilimumab has also been evaluated
for treatment of B-cell lymphoma. In a pilot clinical trial with
four NHL patients after failure of Id vaccination, administra-
tion of ipilimumab showed tumor regression in two patients,
one of which obtained a PR of 14-month duration (O’Mahony
et al., 2007). In a more recent phase I study, 18 patients with
relapsed/refractory B-cell NHL were treated with ipilimumab
(Ansell et al., 2009). Two patients showed clinical responses; one
patient had an ongoing CR (>31months), and one had a PR
lasting 19months. In 5 of 16 cases tested (31%), T-cell prolifera-
tion to recall antigens was signiﬁcantly increased after ipilimumab
therapy. Although response rates have been low in these early
trials, the overall survival beneﬁt observed with ipilimumab in
melanoma prompts further studies. Evaluation of ipilimumab is
ongoing, both as monotherapy and in combination with other
therapies.
Anti-PD-1 mAb. Programmed death-1 (PD-1) is another T-cell
inhibitory receptor that is inducibly expressed after activation
of T-cells. Ligation of PD-1 by its ligands PD-L1 and PD-L2
inhibits T-cell activation. It has been demonstrated that PD-L1
is expressed by NHL and inhibits the activity of tumor-associated
T-cells (Andorsky et al., 2011), suggesting PD-L1 blockade as a
potentially useful strategy for lymphoma immunotherapy. CT-
011 is a humanized anti-PD-1 mAb that has been demonstrated
to induce regression of several tumor types in mice. A phase I
trial using CT-011 in advanced hematologic malignancies demon-
strated some clinical responses including one CR in FL (Berger
et al., 2008). A phase II trial with CT-011 in DLBCL follow-
ing autologous stem cell transplantation has been completed and
publication of data is awaited. According to media releases, CT-
011 met the primary endpoint of improved PFS, and statistically
signiﬁcant results have also been achieved in the secondary end-
point of overall survival. In addition, a phase II trial of CT-011
combined with rituximab in patients with relapsed FL is ongoing
(NCT00904722).
Depletion of Treg
Treg are implicated in the dampening of antitumor T-cell
responses. Accumulating data indicate that the presence of Treg
at the tumor site or in peripheral blood correlates with poor
prognosis (Wilke et al., 2010). In B-cell NHL, Treg at the tumor
site have been shown to suppress activity of inﬁltrating CD4
and CD8 T-cells (Yang et al., 2006a,b), suggesting that Treg
depletion may enhance clinically beneﬁcial antitumor responses.
Denileukin diftitox (Ontak) is a diphtheria toxin-IL-2 fusion pro-
tein shown to deplete Treg in several tumors. In a phase II study
of denileukin diftitox in 29 patients with recurrent indolent B-
cell NHL, three PR were obtained (Kuzel et al., 2007). Despite the
modest clinical response, the prospective introduction of addi-
tional Treg-depleting or Treg-inhibiting reagents may improve the
outcome.
CONCLUSION
Rituximab improved tremendously the management of NHL,
prolonging remission, and survival. However, resistance to rit-
uximab leads to eventual relapse in most patients. Although sev-
eral new generation anti-CD20 mAbs show improved mode of
action compared to rituximab, their clinical efﬁcacy in rituximab-
refractory patients is disappointingly modest. It appears that
type I anti-CD20 mAbs, which comprise the majority of newly
developed anti-CD20 mAbs, do not provide signiﬁcant improve-
ment over rituximab. In contrast, the third-generation type II
mAb GA101 has already shown promising efﬁcacy in rituximab-
refractory patients, and results of phase III trials are awaited.
As it seems that the direct PCD induced by type II anti-CD20
mAbs may be required for elimination of rituximab-resistant
lymphoma cells, efforts should be directed toward rigorous clin-
ical studies of these mAbs, particularly in rituximab-refractory
patients.
Radioimmunotherapy with anti-CD20 mAbs demonstrated
excellent clinical efﬁcacy in chemotherapy and rituximab-
refractory FL. Yet, this treatment is under-utilized, perhaps due
to the complexity of delivery compared to naked antibodies, con-
cerns about late toxicity or uncertainty regarding their integration
with standard therapies. In view of compelling data that the two
approved drugs 131I-tositumomab and 90Y-ibritumomab tiutexan
can signiﬁcantly improve the therapeutic outcome in refractory
disease, their integration in current treatment schemes needs
to be re-examined. If radioimmunotherapy is not adopted by
the clinical community as a more widely used therapeutic tool,
some patients may lose a chance to beneﬁt from this effective
treatment.
Antibodies targeting antigens other than CD20 showed disap-
pointing clinical efﬁcacy. However, drug conjugates such as ino-
tuzumab ozogamicin (anti-CD22) or brentuximab vedotin (anti-
CD30) and bispeciﬁc antibodies such as blinatumomab (anti-
CD19/CD3) have demonstrated impressive clinical efﬁcacy. It is
hoped that these mAbs may improve the outcome in rituximab-
refractory lymphoma, but phase III trials are needed to prove their
superiority.
In comparisonwith the success of anti-CD20mAbs, lymphoma
vaccines appear disappointing. Patients with CR following induc-
tion chemotherapy, in particular patients with an IgM vaccine
isotype, may beneﬁt from Id vaccine therapy. However, a more
effective vaccine is needed for patients who do not achieve min-
imal residual disease. Thus, next generation vaccines are being
developed. These include DNA-based and DC-based Id vaccines
as well as tumor cell vaccines. Optimal vaccine activity will most
probably require combinationwith immune adjuvants that poten-
tiate vaccine-induced antitumor immunity,orwith antibodies that
block immune regulatory checkpoints. Whatever strategies for
vaccine development are selected, lymphoma vaccines will have
to be optimally integrated with standard therapies, particularly
with rituximab.
Finally, in the forthcoming era of personalized medicine, it
will become extremely important to determine which lymphoma
patients are most likely to beneﬁt from a particular therapy out of
the existing therapeutic arsenal. This will likely include tumor and
microenvironment proﬁling by genomic and biomarker analysis.
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